Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics
Iterum Therapeutics plc - Ordinary Share (ITRM)
Today's Latest Price: $1.41 USD
Updated Jan 28 11:15am
Add ITRM to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 241 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ITRM Stock Summary
- Iterum Therapeutics plc's stock had its IPO on May 25, 2018, making it an older stock than only 4.47% of US equities in our set.
- ITRM's price/sales ratio is 1,370.36; that's higher than the P/S ratio of 99.56% of US stocks.
- Revenue growth over the past 12 months for Iterum Therapeutics plc comes in at -95.74%, a number that bests just 0.64% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ITRM, based on their financial statements, market capitalization, and price volatility, are SCYX, CBMG, TOCA, INO, and ITCI.
- ITRM's SEC filings can be seen here. And to visit Iterum Therapeutics plc's official web site, go to www.iterumtx.com.
ITRM Stock Price Chart Interactive Chart >
ITRM Price/Volume Stats
| Current price | $1.41 | 52-week high | $6.02 |
| Prev. close | $1.38 | 52-week low | $0.45 |
| Day low | $1.38 | Volume | 5,025,338 |
| Day high | $1.49 | Avg. volume | 15,691,596 |
| 50-day MA | $1.01 | Dividend yield | N/A |
| 200-day MA | $1.37 | Market Cap | 69.21M |
Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.
Loading social stream, please wait...